Combined as [TIMP-2] × [IGFBP7], these biomarkers form the basis of the NephroCheck® test, which has been Food and Drug Administration (FDA)-cleared for assessing the risk of moderate to severe AKI (KDIGO stage 2–3) within 12–24 h in ICU and post-cardiac surgery settings (Table 2). Here, IGFBP7 is linked to acute kidney injury.